PMID- 34235161
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210709
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction 
      in Patients Undergoing Peritoneal Dialysis.
PG  - 657067
LID - 10.3389/fmed.2021.657067 [doi]
LID - 657067
AB  - Aims: The effect of the angiotensin receptor-neprilysin inhibitor (ARNI) 
      sacubitril-valsartan in patients with heart failure with preserved ejection 
      fraction (HFpEF) remains unclear, and data on ARNI treatment in peritoneal 
      dialysis (PD) patients are lacking. The present study was designed to assess the 
      efficacy and safety of sacubitril-valsartan in patients with HFpEF undergoing 
      peritoneal dialysis. Methods and Results: End-stage kidney disease (ESKD) 
      patients undergoing PD for 3 months with New York Heart Association (NYHA) class 
      II-IV heart failure, ejection fraction of 50% or higher, and elevated levels of 
      N-terminal pro-B-type natriuretic peptide (NT-proBNP) were assigned to receive 
      sacubitril-valsartan. Patients were followed up regularly after medication 
      treatment. The alterations in clinical and biochemical parameters before and 
      after taking sacubitril-valsartan (generally 50-100 mg b.i.d) were investigated, 
      and safety was also assessed. Twenty-one patients were recruited in this study. 
      Compared with baseline levels, NT-proBNP levels [9769.0 (3093.5-21941.0) vs. 
      3034.0 (1493.2-6503.0), P = 0.002], and heart rate [80.0 (74.5-90.5) vs. 75.0 
      (70.3-87.0), P = 0.031] were markedly decreased after treatment with 
      sacubitril-valsartan. Signs and symptoms of heart failure (21/21 vs. 15/21, P = 
      0.021) were obviously alleviated, NYHA classification and E/e' ratio showed a 
      notable trend of improvement after 3-12 months of follow-up. None of the patients 
      showed adverse drug reactions. Conclusions: The present data suggested that 
      sacubitril-valsartan treatment in patients with HFpEF undergoing PD was effective 
      and safe.
CI  - Copyright (c) 2021 Fu, Xu, Lin, Chen, Huang, Xu, Xu, Chen and Tang.
FAU - Fu, Sha
AU  - Fu S
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Xu, Zhenjian
AU  - Xu Z
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Lin, Baojuan
AU  - Lin B
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Chen, Junzhe
AU  - Chen J
AD  - Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, 
      and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong 
      Kong, Hong Kong, China.
FAU - Huang, Qiuyan
AU  - Huang Q
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Xu, Yanchun
AU  - Xu Y
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Xu, Anping
AU  - Xu A
AD  - Department of Nephrology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Chen, Yangxin
AU  - Chen Y
AD  - Department of Cardiology, Guangdong Provincial Key Laboratory of Malignant Tumor 
      Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Tang, Ying
AU  - Tang Y
AD  - Department of Nephrology, The Third Affiliated Hospital, Southern Medical 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210621
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8255468
OTO - NOTNLM
OT  - NT-ProBNP
OT  - heart failure
OT  - peritoneal dialysis
OT  - preserved ejection fraction
OT  - sacubitril-valsartan
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/09 06:00
MHDA- 2021/07/09 06:01
PMCR- 2021/06/21
CRDT- 2021/07/08 06:44
PHST- 2021/01/22 00:00 [received]
PHST- 2021/05/26 00:00 [accepted]
PHST- 2021/07/08 06:44 [entrez]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/07/09 06:01 [medline]
PHST- 2021/06/21 00:00 [pmc-release]
AID - 10.3389/fmed.2021.657067 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Jun 21;8:657067. doi: 10.3389/fmed.2021.657067. 
      eCollection 2021.